Content about Science and technology in Israel

April 17, 2014

Teva Pharmaceutical announced that its U.S. subsidiary has entered into a settlement with Pfizer related to Teva's generic version of Celebrex (celecoxib) 50-, 100-, 200- and 400-mg capsules in the United States.

JERUSALEM — Teva Pharmaceutical on Thursday announced that its U.S. subsidiary has entered into a settlement with Pfizer related to Teva's generic version of Celebrex (celecoxib) 50-, 100-, 200- and 400-mg capsules in the United States.

Under the terms of the settlement, Teva may launch its generic versions in December, 2014, or earlier under certain circumstances. Teva has received tentative approval from the Food and Drug Administration for all strengths and believes that it is first-to-file on at least the 100-, 200- and 400-mg capsules. 

April 8, 2014

Teva Pharmaceutical Industries announced that it has received approval from the Food and Drug Administration for its generic form of Lovaza (omega-3-acid ethyl esters capsules, USP) in the United States.

JERUSALEM — Teva Pharmaceutical Industries announced that it has received approval from the Food and Drug Administration for its generic form of Lovaza (omega-3-acid ethyl esters capsules, USP) in the United States.

Lovaza is used as an adjunct to diet to reduce triglycerdide levels in adult patients, according to the FDA. Teva believes it is the first to file and plans to begin shipping immediately.

Lovaza capsules, marketed by GlaxoSmithKline, had annual sales of $1.1 billion in the United States as of December 2013, according to IMS data.

 

March 10, 2014

Teva Pharmaceuticals USA, a subsidiary of Teva Pharmaceutical Industries, and Volunteers in Medicine, a national nonprofit organization dedicated to helping communities provide free primary healthcare clinics for families and individuals, have announced their 2014 National Partnership to make healthcare services more readily available to the uninsured.

NORTH WALES, Pa. and BURLINGTON, Vt. — Teva Pharmaceuticals USA, a subsidiary of Teva Pharmaceutical Industries, and Volunteers in Medicine, a national nonprofit organization dedicated to helping communities provide free primary healthcare clinics for families and individuals, have announced their 2014 National Partnership to make healthcare services more readily available to the uninsured.

March 7, 2014

Teva Pharmaceutical Industries will launch the generic version of Xeloda (capecitabine) tablets, 150 mg and 500 mg, in the United States.

JERUSALEM — Teva Pharmaceutical Industries will launch the generic version of Xeloda (capecitabine) tablets, 150 mg and 500 mg, in the United States. The drug is used to treat cancers that have metastasized.

Xeloda tablets, 150 mg and 500 mg had annual sales in the United States of approximately $754 million as of December 2013, according to IMS.

 

February 13, 2014

Teva Pharmaceutical Industries announced that the Food and Drug Administration has granted full approval of Synribo (omacetaxine mepesuccinate) for injection.

JERUSALEM — Teva Pharmaceutical Industries on Thursday announced that the Food and Drug Administration has granted full approval of Synribo (omacetaxine mepesuccinate) for injection.

The drug is indicated for adult patients with chronic phase or accelerated phase chronic myeloid leukemia with resistance and/or intolerance to two or more tyrosine kinase inhibitors.

January 21, 2014

Teva Pharmaceutical announced that it has entered into a definitive agreement under which Teva will acquire NuPathe for $3.65 per share in cash.

JERUSALEM — Teva Pharmaceutical on Tuesday announced that it has entered into a definitive agreement under which Teva will acquire NuPathe for $3.65 per share in cash, or approximately $144 million. In addition to the upfront cash payment, NuPathe shareholders will receive rights to receive additional cash payments of up to $3.15 per share if specified net sales of NuPathe's migraine treatment, Zecuity, are achieved over time.

January 9, 2014

Teva Pharmaceutical Industries has appointed Erez Vigodman as president and CEO, the Israeli drug maker said Thursday.

JERUSALEM — Teva Pharmaceutical Industries has appointed Erez Vigodman as president and CEO, the Israeli drug maker said Thursday.

Vigodman will replace acting president and CEO Eyal Desheh, who will return to his previous position as group EVP and CFO. Desheh took the interim position after the departure of former president and CEO Jeremy Levin in October 2013.

January 7, 2014

Ani Pharmaceuticals has bought 31 generic drugs from Teva Pharmaceuticals for $12.5 million, the company said.

BAUDETTE, Minn. — Ani Pharmaceuticals has bought 31 generic drugs from Teva Pharmaceuticals for $12.5 million, the company said.

January 3, 2014

Teva Pharmaceutical Industries has launched an authorized generic version of a drug used to treat overactive bladder, the company said Friday.

JERUSALEM — Teva Pharmaceutical Industries has launched an authorized generic version of a drug used to treat overactive bladder, the company said Friday.

December 10, 2013

Teva Pharmaceutical Industries anticipates that it could lose about $500 million in sales next year if a generic version of its multiple sclerosis drug hits the market, the Israeli drug maker said Tuesday.

JERUSALEM — Teva Pharmaceutical Industries anticipates that it could lose about $500 million in sales next year if a generic version of its multiple sclerosis drug hits the market, the Israeli drug maker said Tuesday.

December 6, 2013

Teva Pharmaceutical Industries' U.S. subsidiary has launched a generic drug for treating warts and skin lesions, the company said.

NORTH WALES, Pa. — Teva Pharmaceutical Industries' U.S. subsidiary has launched a generic drug for treating warts and skin lesions, the company said.

Teva Pharmaceuticals announced the launch and availability of imiquimod cream, a generic version of Medicis Pharmaceutical Corp.'s Aldara.

The drug is used to treat external genital and rectal warts, certain types of actinic keratosis and basal cell carcinoma. Various versions of the drug had sales of about $244 million in 2011, according to IMS Health.

 

December 2, 2013

The Food and Drug Administration has designated a drug made by Teva Pharmaceutical Industries as an orphan drug, the company said.

JERUSALEM — The Food and Drug Administration has designated a drug made by Teva Pharmaceutical Industries as an orphan drug, the company said.

Teva said the drug, Treanda (bendamustine hydrochloride), received the designation for indolent B-cell non-Hodgkins lymphoma through October 2015 that has progressed during or within six months of treatment with a regimen containing Rituxan (rituximab), marketed by Genentech and Biogen Idec. The FDA gives orphan drug designation to treatments for diseases affecting fewer than 200,000 people in the United States.

November 22, 2013

Teva Pharmaceutical Industries has launched its generic version of a drug for patients with cystic fibrosis, the Israeli drug maker said Thursday.

JERUSALEM — Teva Pharmaceutical Industries has launched its generic version of a drug for patients with cystic fibrosis, the Israeli drug maker said Thursday.

Teva announced the launch of tobramycin inhalation solution, a generic version of Novartis' drug Tobi. The Food and Drug Administration approved Teva's product last month. The drug is used to treat CF in patients whose lungs contain bacteria called Pseudomonas aeroginosa.

Tobi had sales of about $350 million during the 12-month period that ended in June, according to IMS Health.

 

November 1, 2013

Teva Pharmaceutical Industries had $5.1 billion in sales and $711 million in profits in third-quarter 2013, the Israeli drug maker said.

JERUSALEM — Teva Pharmaceutical Industries had $5.1 billion in sales and $711 million in profits in third-quarter 2013, the Israeli drug maker said.

October 30, 2013

Teva Pharmaceutical Industries' president and CEO has stepped down, the Israeli drug maker said.

JERUSALEM — Teva Pharmaceutical Industries' president and CEO has stepped down, the Israeli drug maker said.

Teva announced the resignation of Jeremy Levin and that the board of directors had named EVP and CFO Eyal Desheh as interim president and CEO. Desheh has worked at Teva for more than 12 years, serving as CFO for the last five.

October 22, 2013

Teva Pharmaceutical Industries is investing more than $100 million in its Croatian division for a plant that will make pills mostly for the international market.

ZAGREB, Croatia — Teva Pharmaceutical Industries is investing more than $100 million in its Croatian division for a plant that will make pills mostly for the international market.

Teva subsidiary Pliva said the new plant, in the capital of Zagreb, would considerably increase its production capacities for tablets and capsules. The company said the new plant would increase the annual manufacturing capacity by more than 25%.

October 7, 2013

Late-stage clinical data support the efficacy of an experimental drug under development by Teva Pharmaceutical Industries and Active Biotech for multiple sclerosis, the two companies said.

JERUSALEM — Late-stage clinical data support the efficacy of an experimental drug under development by Teva Pharmaceutical Industries and Active Biotech for multiple sclerosis, the two companies said.

October 1, 2013

Generic drug maker Teva Pharmaceutical Industries has launched a version of a drug used to treat a parathyroid disorder related to kidney disease.

JERUSALEM — Generic drug maker Teva Pharmaceutical Industries has launched a version of a drug used to treat a parathyroid disorder related to kidney disease.

Teva announced Tuesday the launch of paricalcitol, a generic version of AbbVie's Zemplar. As the first company to win Food and Drug Administration approval for the drug, Teva has 180 days in which to compete directly with the branded version.

September 25, 2013

Teva Pharmaceutical Industries has become the first to launch a generic drug for treating certain heart patients, the company said.

JERUSALEM — Teva Pharmaceutical Industries has become the first to launch a generic drug for treating certain heart patients, the company said.

Teva announced the launch of adenosine injection, a generic version of Astellas Pharma's Adenoscan. The drug is used in combination with thallium-201 in patients undergoing myocardial perfusion scintigraphy who are unable to exercise adequately.

September 23, 2013

Teva Pharmaceutical Industries has launched a generic drug for treating cardiovascular disease, the company said.

JERUSALEM — Teva Pharmaceutical Industries has launched a generic drug for treating cardiovascular disease, the company said.

Teva announced the launch of niacin extended-release tablets in the 500-mg, 750-mg and 1,000-mg strengths. As the first company to file for approval of the drug, Teva will have 180 days in which to market the generic version exclusively.

September 17, 2013

The participation of reality TV star Jack Osbourne in "Dancing with the Stars" has garnered recognition and a donation from a drug maker.

FRAZER, Pa. — The participation of reality TV star Jack Osbourne in "Dancing with the Stars" has garnered recognition and a donation from a drug maker.

Teva Pharmaceuticals said Tuesday it would donate $100,000 to the National Multiple Sclerosis Society to recognize Osbourne's decision to compete in the show. Osbourne, the son of rock musician Ozzy Osbourne and a television host and producer, was diagnosed with relapsing-remitting MS last year. Teva is the maker of Copaxone (glatiramer acetate), an injectable drug for the disease.

September 17, 2013

The Food and Drug Administration has approved a new formulation of a cancer drug made by Teva Pharmaceutical Industries, Teva said Tuesday.

JERUSALEM — The Food and Drug Administration has approved a new formulation of a cancer drug made by Teva Pharmaceutical Industries, Teva said Tuesday.

The Israeli drug maker announced the approval of a liquid formulation of Treanda (bendamustine hydrochloride), which it said would eliminate the need for reconstitution.

The drug is used to treat indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with Rituxan (rituximab), which is made by Genentech and Biogen Idec, and in patients with chronic lymphocytic leukemia.

September 10, 2013

Teva Pharmaceutical Industries has introduced a generic version of an antibiotic drug kit, the company said.

NORTH WALES, Pa. — Teva Pharmaceutical Industries has introduced a generic version of an antibiotic drug kit, the company said.

Teva, through U.S. subsidiary Teva Pharmaceuticals, announced the introduction of 30-mg lansoprazole delayed-release capsules, 500-mg amoxicillin capsules and 500-mg clarithromycin tablets. The treatment is packaged in 14 cards with eight pills, designed for 14 days of treatment.

The treatment is a generic version of Takeda's Prevpac Kit.

 

August 12, 2013

Teva Pharmaceutical and Perrigo Co. announced the launch of the generic equivalent to Temodar (temozolomide). Teva will manufacture, market and distribute the product in the United States, and both companies will equally share in the cost and profitability of the product in the country.

JERUSALEM and ALLEGAN, Mich. — Teva Pharmaceutical Industries Ltd., and Perrigo Co. today announced the launch of the generic equivalent to Temodar (temozolomide). Teva will manufacture, market and distribute the product in the United States, and both companies will equally share in the cost and profitability of the product in the country. Teva was first to file, making the product eligible for 180 days of marketing exclusivity.

July 26, 2013

A federal court has ruled in favor of generic drug maker Sandoz in a case involving a drug for multiple sclerosis, Sandoz said.

PRINCETON, N.J. — A federal court has ruled in favor of generic drug maker Sandoz in a case involving a drug for multiple sclerosis, Sandoz said.

Sandoz, the generics division of Switerland-based Novartis, said the U.S. Federal Circuit Court of Appeals invalidated nine patents owned by Israel-based Teva Pharmaceutical Industries covering the drug Copaxone (glatiramer acetate).